152 results
Page 4 of 8
6-K
EX-99.1
cwq8o2esm8d2 cybe
24 Jun 19
Acasti Pharma Awarded Notice of Allowance for a Second Patent in China Covering CaPre’s Omega-3 Phospholipid Composition
9:01am
6-K
EX-99.1
25gf7xzkwr5o
19 Jun 19
Acasti Pharma Schedules Fourth Quarter and Fiscal 2019 Conference Call
8:00am
6-K
EX-99.1
nt763clj516c622jvg7
4 Jun 19
Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100% Patient Randomization Target in Patients with Severe Hypertriglyceridemia
9:15am
6-K
EX-99.1
d8rg56854pixhsx3w2ds
21 May 19
Acasti Pharma to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
7:31am
6-K
EX-99.1
9z7d8c1
15 May 19
Acasti Pharma Awarded Notices of Allowance for Additional Composition & Use Patents in Mexico, Chile and Israel
7:56am
6-K
EX-99.1
7teis 3xclkczz
10 May 19
Current report (foreign)
10:05am
6-K
EX-99.1
x6x8alg8lo 5rpup15x
24 Apr 19
Acasti Pharma CEO to Present at the ThinkEquity Conference on May 2nd in New York City
8:35am
6-K
EX-99.1
l14xsxys78h zt9w
15 Apr 19
Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia
9:15am
6-K
EX-99.1
iatfg
26 Mar 19
Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd
8:30am
6-K
EX-99.1
a887o5k2q5a8z3w
13 Mar 19
Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th
8:30am
6-K
EX-99.1
94g96u fupifc
21 Feb 19
Current report (foreign)
9:15am
6-K
EX-99.1
v5elkrmgk sopn
14 Feb 19
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
8:05am
6-K
EX-99.1
kv00w oe9zt52
14 Feb 19
Current report (foreign)
7:55am
6-K
EX-99.1
8olgk58e8l
8 Feb 19
Acasti Pharma Schedules Third Quarter Fiscal 2019 Conference Call
8:05am
6-K
EX-99.1
t92xex4z
9 Jan 19
Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office
8:05am
6-K
EX-99.1
sgmg6s8ueuzwj8tob3w
31 Dec 18
Current report (foreign)
8:00am
6-K
EX-99.1
ad8nz77hn5vey2fna6
20 Dec 18
Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia
8:01am
6-K
EX-99.1
sagv8ehyds3hqg
14 Nov 18
Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019
8:05am
6-K
EX-99.1
7z3lmxdi5vfyqppq
14 Nov 18
Current report (foreign)
7:00am
6-K
EX-99.1
5f4ks0 pm
7 Nov 18
Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call
8:01am